# A001 · Could evolv contribute to Pistoia work like "AI Adoption in Clinical Trials" as a Snowflake SI?

*Question from 2026-10-22. Evidence drawn from S002, S003, S007, S011, S014, S015, S017, S018, S019 plus targeted searches. v1.*

## Bottom line

**Yes. There's clear precedent for services firms contributing to Pistoia, and evolv has a credible, distinct lane.** The lane is **not** "Snowflake partner" and **not** ontology authoring. It's the layer Pistoia's own materials say is missing: **landing standards in governed data products, making AI on that data trustworthy to regulators, and measuring whether it delivers value.** Show up as a neutral expert who happens to build on Snowflake, never as a reseller.

**Confidence: medium.** Precedent and demand are well evidenced. Membership terms for service providers, and whether Snowflake itself has any Pistoia presence, are still unconfirmed.

---

## Evidence for

| Evidence | Source | Strength |
|---|---|---|
| Pistoia welcomes "any organization that can contribute"; members include CROs, technology and service providers | [Membership page](https://pistoiaalliance.org/membership/) via search | Medium (search excerpt) |
| **Accenture** appears on Pistoia's own member slide (May 2026); Cognizant, EPAM, and Karchem Consulting are listed members | [S015](../sources/S015-pistoia-pgo-terminology-bioit-2026.md) (primary); search | **High** |
| **ZS** (consultancy) co-hosts the CMC Process Ontology workshop with AbbVie and is a named Phase 3 supporter. Pistoia explicitly invited "technology vendors" as sponsors and contributors | [Pistoia CMC Phase 3](https://pistoiaalliance.org/?p=27053); [Manufacturing Chemist](https://manufacturingchemist.com/pistoia-alliance-launches-phase-3-cmc-process-ontology) | **High** |
| **Thoughtworks** (consultancy) sponsored the April 2026 conference poll and published an e-book from it | [S018](../sources/S018-pistoia-london-2026-conference-poll.md) | **High** |
| Services and specialist firms contribute to standards: The Hyve and Curlew Research (FAIR Maturity Matrix); Global Value Web (IDMP-O governance); MAIN5 (EMA PMS delivery with Accurids) | [S007](../sources/S007-fair-maturity-matrix.md), [S003](../sources/S003-pistoia-idmp-o-info-sheet.md), [S014](../sources/S014-accurids.md) | High |
| Contribution roles are explicit for members: **User, Expert, Sponsor** | [S015](../sources/S015-pistoia-pgo-terminology-bioit-2026.md) | **High** |
| Clinical-trial AI demand sits in the data layer: **48%** expect most impact in data cleaning, analysis, and insight **[verify]**; **50%** cite trust and regulatory uncertainty as the top barrier | [S017](../sources/S017-pistoia-ai-adoption-clinical-trials-poll.md) | Medium–High |
| **69%** can't measure AI's R&D impact; **59%** say prioritize data quality and accessibility; regulatory reporting benefits most (**54%**) | [S018](../sources/S018-pistoia-london-2026-conference-poll.md) | High |
| Project maturity, not technology, predicts AI business success | [S011](../sources/S011-pistoia-nlp-llm-use-case-collection.md) | **High** (peer-reviewed) |
| Pistoia's own vision is **data products**: "A CRO delivers a data product tagged with PGO-T URIs… the receiving pharma company's knowledge graph ingests it directly" | [S015](../sources/S015-pistoia-pgo-terminology-bioit-2026.md) | **High** |
| Snowflake life-sciences momentum: Sanofi chose Snowflake for AI-powered drug development (June 2026); eClinical Solutions' clinical data cloud integrates bidirectionally with Snowflake; secure data sharing and clean rooms are positioned for sponsor–CRO exchange | [Business Wire](https://www.businesswire.com/news/home/20260602582503/en/Sanofi-Chooses-Snowflake-to-Accelerate-its-AI-Powered-Drug-Development); [Clinical Trial Vanguard](https://www.clinicaltrialvanguard.com/news/eclinical-solutions-and-snowflake-partner-for-life-sciences/); partner sites | Medium (vendor-sourced) |

## Evidence against, and risks

| Risk | Why it matters | Mitigation |
|---|---|---|
| **No evidence Snowflake is a Pistoia member or project participant** (searches found none). Its top HCLS SIs and data partners *are* in Pistoia, though (Accenture, Cognizant, ZS, Benchling, IQVIA; see [A002](A002-pistoia-vs-snowflake-si-world.md)) | You can't borrow Snowflake's standing, and large SIs already straddle both worlds | Contribute as evolv, narrower and deeper; treat "bring Snowflake into Pistoia" as a later, optional move |
| **Pistoia is vendor-neutral and precompetitive.** One stated member benefit is "creating consensus-based requirements for key vendors" | A platform pitch inside a project would damage credibility | Platform-neutral contributions; any Snowflake work framed as *one* reference implementation of an open pattern |
| **Ontology authoring runs on semantic-web tooling** (OWL, LinkML, RDF), not data warehouses | Snowflake isn't where PGO-T or ClinOps is *written* | Contribute where standards **land**: data products, tagging, governance, sharing, AI, value measurement |
| **Bigger consultancies are already there** (Accenture, ZS, Thoughtworks, Cognizant, EPAM) | evolv competes for attention and roles | Pick one narrow, under-served lane and own it |
| **Membership fee for service providers unknown** (pharma tiers seen: $8,400 and $21,000 p.a.) | Budget and ROI case | Ask Pistoia directly; start with events and webinars before committing |
| Clinical poll sub-figures (42%, 48%, 22%) are from trade coverage | Don't over-quote | Get the poll PDF before using them externally |

## Where evolv fits in Pistoia's stack

```
AUTHORING   Ontologies & terminologies (PGO-T, IDMP-O, ClinOps, CMC-PO)       ← ontologists, pharma experts
               │  OWL / LinkML / RDF
LANDING     Tagged data products · governed sharing (sponsor ↔ CRO) ·        ← evolv's lane (data platform)
            lineage & audit · data quality automation
               │
ADOPTION    AI on trusted data · explainability for regulators ·             ← evolv's lane (practice + buyer-side background)
            value measurement · change & ownership
```

Pistoia's materials say the authoring layer is in hand. The **landing and adoption layers** are what members keep naming as gaps: data quality (59%), trust and regulatory clarity (50%), measurement (69%), maturity (S011).

## Options (crawl → walk → run)

| Option | What it looks like | Effort | Payoff |
|---|---|---|---|
| **1. Show up** | Attend Pistoia webinars and events (UXLS, London, US conference); join a community of interest | Low | Relationships, signal on where projects are forming |
| **2. Contribute evidence** | Submit anonymized client cases (with permission) to the **NLP/LLM Use Case Database** ([S011](../sources/S011-pistoia-nlp-llm-use-case-collection.md)) | Low–Med | Visibility with the people who analyze AI success; credibility through data, not pitch |
| **3. Expert seat** | As a member, offer data-platform expertise to **PGO-T Phase 2/3** (machine-readable schemas, mappings) or **ClinOps** (clinical data products) | Med | Named contributor on a standard pharma funds; deep relationships with funders' data leaders |
| **4. Neutral reference pattern** | Publish an open pattern: "landing PGO-T / ClinOps-tagged clinical data products with governed sponsor–CRO sharing," with Snowflake as one worked implementation | Med–High | Concrete proof of the "landing layer"; natural Snowflake co-sell story outside Pistoia |
| **5. Sponsor a poll or insight** | Like Thoughtworks: co-design a conference poll on a topic to own, e.g., *"Is your clinical data trustworthy enough for AI?"* or *"How do you measure AI value?"* | Med (sponsorship cost) | Headline numbers with your name in trade press; content engine for a year |
| **6. Sponsor a project phase** | Fund part of PGO-T Phase 3 or a clinical-data initiative | High | Steering-group seat; usually reserved for pharma |

**Recommended starting combination: 1 + 2 + 5.** A poll on **AI value measurement in clinical and regulatory work** fits evolv's strongest themes (T8, T6), the 69% gap, and "deliver visible value incrementally." Add **3 or 4** once a relationship exists.

## Current state → future state → gap (for evolv)

| Current state | Future state | Gap |
|---|---|---|
| Snowflake HCLS practice; no Pistoia presence | Recognized neutral contributor on AI-ready, trustworthy data in life sciences | Membership decision; one focused contribution |
| Pitch framed around platform and AI demos | Framed around standards-aligned data products, regulator-ready trust, measured value | Messaging aligned to Pistoia vocabulary (FAIR, PGO-T, ClinOps, maturity) |
| Snowflake co-sell motion separate from consortium work | Neutral reference pattern that also powers the co-sell story | Reference implementation and write-up |

## Questions to resolve (ask Pistoia directly)
1. Membership tier and fee for a **services firm** of evolv's size? (The [membership overview PDF](https://marketing.pistoiaalliance.org/hubfs/Membership/Pistoia_Alliance_Membership_Overview.pdf) may have it.)
2. Is a **clinical-trials AI project or community** forming after the May 2026 poll?
3. Are poll sponsorships open for the next conference, and at what cost?
4. Is **PGO-T Phase 3** or **ClinOps** looking for data-platform expertise?
5. Ask Snowflake's HCLS team: any interest in, or history with, Pistoia?

## Suggested one-line positioning for a Pistoia conversation
> "evolv helps life sciences teams land standards like PGO-T and IDMP-O in governed data products on the platforms they already run, and measure whether the AI built on them actually delivers value."
